10.3969/j.issn.1672-5123.2006.03.020 69 LiX.JingN.LiuX
OTRAS PRESENTACIONES: $135,000 IVA incl
Because Retatrutide is a GLP-1-class agonist, the well-established class safety warnings apply as reference context: Thyroid C-cell tumors / MTC (boxed-warning class effect): GLP-1 receptor agonists carry a boxed warning for thyroid C-cell tumors based on rodent data
Track These Simple Symptom Categories Nausea level (none, mild, moderate, severe) Reflux or heartburn (especially at night) Constipation or diarrhea (frequency and comfort) Hydration (dry mouth, dizziness, dark urine) Food intake patterns (especially protein and fluids) Energy and sleep (because fatigue can signal under-fueling or dehydration) Also, note the timing
Its primary endpoint was measured at week 72, not at week 4 or week 12, and the trial's own structure tells you something: the sponsor and the FDA both expected meaningful change to accumulate across more than a year of treatment
While FDA approval is specific to HIV-associated lipodystrophy, tesamorelin is prescribed off-label for visceral fat reduction and body composition optimization in broader populations
